Use of multikinase inhibitors/lenvatinib in patients with high cardiovascular risk/vasculopathy and radioiodine refractory‐differentiated thyroid cancer
Abstract Antiangiogenic tyrosine kinase inhibitors are the treatment of choice in radioiodine refractory‐differentiated thyroid cancer (RR‐DTC). Nevertheless, these therapies present class toxicities that may impact their feasibility and patient's quality of life. Their mechanism of action explains...
Na minha lista:
| Autor principal: | |
|---|---|
| Formato: | Artigo |
| Idioma: | Inglês |
| Publicado em: |
Wiley
2022-10-01
|
| coleção: | Cancer Medicine |
| Assuntos: | |
| Acesso em linha: | https://doi.org/10.1002/cam4.5127 |
| Tags: |
Sem tags, seja o primeiro a adicionar uma tag!
|